Rosetta Genomics to expand research facility
MicroRNA diagnostics and therapeutics company Rosetta Genomics is to expand its Israeli research facility.
MicroRNA diagnostics and therapeutics company Rosetta Genomics is to expand its Israeli research facility.
The company is adding the new laboratories to its state-of-the-art facilities to meet its r&d needs for its microRNA-based diagnostic programmes. The company expects to grow to approximately 70 employees by the end of the year.
"This expansion will enable us to advance new development programmes, and accommodate the large number of scientists that have joined Rosetta recently and those we expect to add in the future," said Amir Avniel, Rosetta Genomics' ceo.
"Our proprietary discovery platform is capable of utilising more than 12,000 predicted and validated microRNAs, including more than 1,000 proprietary microRNAs, which are expressed in different tissues. This platform provides us with the foundation upon which we can advance microRNA-based diagnostic products in key oncology indications. The new lab space is essential for the success of these efforts."